Abstract
BackgroundBelimumab, a B-lymphocyte stimulator, was FDA-approved March 2011 for the treatment of adult patients with active, autoantibody-positive SLE receiving standard of care medications. There is a need to evaluate belimumab's...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have